Analytical Data
-
基因名
KLK13
- Application
-
别名
KLK13;KLKL4;Kallikrein-13
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UKR3
-
表达区间
17-262aa
-
氨基酸序列
GGVSQESSKVLNTNGTSGFLPGGYTCFPHSQPWQAALLVQGRLLCGGVLV HPKWVLTAAHCLKEGLKVYLGKHALGRVEAGEQVREVVHSIPHPEYRRSP THLNHDHDIMLLELQSPVQLTGYIQTLPLSHNNRLTPGTTCRVSGWGTTT SPQVNYPKTLQCANIQLRSDEECRQVYPGKITDNMLCAGTKEGGKDSCEG DSGGPLVCNRTLYGIVSWGDFPCGQPDRPGVYTRVSRYVLWIRETIVDHH HHHH
-
分子量
28 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KLK13, also known as kallikrein-related peptidase 13, is a member of the kallikrein family of serine proteases, which are implicated in various physiological processes, including inflammation, tissue remodeling, and cancer progression. Originally identified due to its aberrant expression in cancer tissues, KLK13 has garnered attention for its potential role as a biomarker for certain malignancies, particularly prostate cancer. Researchers have focused on the recombinant production of KLK13 to facilitate in-depth studies of its structure, function, and interactions with other proteins. By generating KLK13 in a controlled laboratory setting, scientists are able to analyze its enzymatic activity, substrate specificity, and regulatory mechanisms. Furthermore, understanding KLK13's involvement in proteolytic pathways may contribute insights into its potential therapeutic applications. Through the study of KLK13 and its recombinant form, the scientific community aims to elucidate its roles in tumor biology and explore its viability as a target for innovative cancer treatments, thereby advancing the field of oncological research and improving patient outcomes.
